|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Mean Corpuscular Volume (result)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.
|
25117820 |
2014 |
|
Waist Circumference
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium.
|
19557197 |
2009 |
|
Parkinson Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Both SV2B and SV2C are increasingly implicated in diseases such as Alzheimer's disease and Parkinson's disease.
|
31394034 |
2019 |
|
Parkinson Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
SV2C has been linked to multiple neurological disorders, including Parkinson's disease and psychiatric conditions.
|
29274878 |
2019 |
|
Parkinson Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
These data establish SV2C as a mediator of dopamine neuron function and suggest that SV2C disruption is a unique feature of PD that likely contributes to dopaminergic dysfunction.
|
28246328 |
2017 |
|
Parkinson Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Taken together, cross-validating evidence from humans and Drosophila suggests SV2C is involved in PD pathogenesis and it might be a useful marker for pharmacogenomics studies involving nicotine.
|
23032990 |
2013 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Both SV2B and SV2C are increasingly implicated in diseases such as Alzheimer's disease and Parkinson's disease.
|
31394034 |
2019 |
|
nervous system disorder
|
0.020 |
Biomarker
|
group |
BEFREE |
SV2C has been linked to multiple neurological disorders, including Parkinson's disease and psychiatric conditions.
|
29274878 |
2019 |
|
Alzheimer's Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, SV2C expression is dramatically altered in postmortem brain tissue from PD cases but not in Alzheimer disease, progressive supranuclear palsy, or multiple system atrophy.
|
28246328 |
2017 |
|
Hypertensive disease
|
0.020 |
Biomarker
|
group |
BEFREE |
In addition, recent researches have shown that SV2C regulates hypertension and accelerates venous thromboembolism (VTE) and coagulation pathways and may play roles in several non-nervous system diseases.
|
28774501 |
2017 |
|
nervous system disorder
|
0.020 |
Biomarker
|
group |
BEFREE |
In addition, recent researches have shown that SV2C regulates hypertension and accelerates venous thromboembolism (VTE) and coagulation pathways and may play roles in several non-nervous system diseases.
|
28774501 |
2017 |
|
Hypertensive disease
|
0.020 |
GeneticVariation
|
group |
BEFREE |
A genetic variant in SV2C predicted clinically relevant bevacizumab-induced hypertension in two independent, randomised phase III trials.
|
25117820 |
2014 |
|
Huntington Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, in the TG mouse brain there was a dramatic decrease in the protein level of SV2C, which has a restricted distribution pattern in regions particularly vulnerable in HD.
|
29713895 |
2018 |
|
Psychotic Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
As SV2C may provide a potential novel therapeutic target for psychosis and other diseases, this article reviews the progress made thus far in understanding the structure, distribution, function and regulation of SV2C.
|
28774501 |
2017 |
|
Nonorganic psychosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
As SV2C may provide a potential novel therapeutic target for psychosis and other diseases, this article reviews the progress made thus far in understanding the structure, distribution, function and regulation of SV2C.
|
28774501 |
2017 |
|
Venous Thromboembolism
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In addition, recent researches have shown that SV2C regulates hypertension and accelerates venous thromboembolism (VTE) and coagulation pathways and may play roles in several non-nervous system diseases.
|
28774501 |
2017 |
|
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
SV2A, B proteins were identified in non-tumor (MCF-10A) and tumor cell lines (MDA-MB-231 and T47D) while SV2C only was found in the T47D cell line.
|
23244111 |
2012 |
|
Epilepsy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
None of the polymorphisms tested in SV2A, SV2B or SV2C influence LEV response or predisposition to epilepsy.
|
18977120 |
2009 |